JP2018525994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525994A5 JP2018525994A5 JP2018510109A JP2018510109A JP2018525994A5 JP 2018525994 A5 JP2018525994 A5 JP 2018525994A5 JP 2018510109 A JP2018510109 A JP 2018510109A JP 2018510109 A JP2018510109 A JP 2018510109A JP 2018525994 A5 JP2018525994 A5 JP 2018525994A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- sample
- splice variants
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 23
- 239000000523 sample Substances 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 13
- 101000707567 Homo sapiens Splicing factor 3B subunit 1 Proteins 0.000 claims 10
- 102100031711 Splicing factor 3B subunit 1 Human genes 0.000 claims 10
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000005787 hematologic cancer Diseases 0.000 claims 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000001613 neoplastic effect Effects 0.000 claims 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 3
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 3
- 238000001574 biopsy Methods 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000000601 blood cell Anatomy 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 230000003538 neomorphic effect Effects 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 206010046766 uterine cancer Diseases 0.000 claims 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021074145A JP7256840B2 (ja) | 2015-09-01 | 2021-04-26 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562212876P | 2015-09-01 | 2015-09-01 | |
| US62/212,876 | 2015-09-01 | ||
| PCT/US2016/049490 WO2017040526A2 (en) | 2015-09-01 | 2016-08-30 | Splice variants associated with neomorphic sf3b1 mutants |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021074145A Division JP7256840B2 (ja) | 2015-09-01 | 2021-04-26 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018525994A JP2018525994A (ja) | 2018-09-13 |
| JP2018525994A5 true JP2018525994A5 (OSRAM) | 2019-10-10 |
| JP6876680B2 JP6876680B2 (ja) | 2021-05-26 |
Family
ID=56936518
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510109A Active JP6876680B2 (ja) | 2015-09-01 | 2016-08-30 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
| JP2021074145A Active JP7256840B2 (ja) | 2015-09-01 | 2021-04-26 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021074145A Active JP7256840B2 (ja) | 2015-09-01 | 2021-04-26 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10889866B2 (OSRAM) |
| EP (2) | EP3910073B1 (OSRAM) |
| JP (2) | JP6876680B2 (OSRAM) |
| ES (1) | ES2887201T3 (OSRAM) |
| WO (1) | WO2017040526A2 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3910073B1 (en) | 2015-09-01 | 2024-03-06 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic sf3b1 mutants |
| EP3596235A1 (en) * | 2017-03-15 | 2020-01-22 | Eisai R&D Management Co., Ltd. | Spliceosome mutations and uses thereof |
| WO2019027987A2 (en) * | 2017-07-31 | 2019-02-07 | The Johns Hopkins University | COMPOSITIONS AND METHODS FOR TARGETING MASAS TO TREAT CANCERS WITH SPLICE COMPLEX MUTATIONS |
| WO2019199667A2 (en) * | 2018-04-09 | 2019-10-17 | Keaney Gregg F | Certain pladienolide compounds and methods of use |
| AU2019279012A1 (en) | 2018-06-01 | 2020-12-24 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
| IL262658A (en) * | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
| JP6931860B2 (ja) * | 2019-02-08 | 2021-09-08 | 株式会社Ｚｅｎｉｃｋ | ｍＲＮＡ前駆体の解析方法、情報処理装置、コンピュータプログラム |
| US20220073971A1 (en) * | 2019-02-08 | 2022-03-10 | Zenick Corporation | Method for analyzing mrna precursor, information processing apparatus, and computer program |
| US20230159920A1 (en) * | 2019-06-26 | 2023-05-25 | Fred Hutchinson Cancer Research Center | Methods and compositions comprising brd9 activating therapies for treating cancers and related disorders |
| CN111518805A (zh) * | 2020-04-30 | 2020-08-11 | 北京航空航天大学 | 一种可用于抑制肿瘤增殖的非编码基因及其应用 |
| ES2891182A1 (es) * | 2020-07-14 | 2022-01-26 | Servicio Andaluz De Salud | Compuestos para el tratamiento del carcinoma hepatocelular |
| CN116507334A (zh) * | 2020-11-04 | 2023-07-28 | 卫材R&D管理有限公司 | 骨髓增生异常综合征（mds）的生物标记物及其使用方法 |
| CA3199753A1 (en) | 2020-11-04 | 2022-05-12 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| WO2023209074A1 (en) * | 2022-04-28 | 2023-11-02 | Institut National de la Santé et de la Recherche Médicale | Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6372431B1 (en) * | 1999-11-19 | 2002-04-16 | Incyte Genomics, Inc. | Mammalian toxicological response markers |
| KR100751105B1 (ko) | 2000-02-18 | 2007-08-22 | 센텔리옹 에스아에스 | 작용화된 폴리알킬렌이민의 제조방법, 이를 함유하는조성물 및 이의 용도 |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| TWI311558B (en) | 2001-02-01 | 2009-07-01 | Mercian Corporatio | Novel physiologically active substance |
| US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
| US20070015271A1 (en) * | 2002-04-04 | 2007-01-18 | Rosen Craig A | Human secreted proteins |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| US7576204B2 (en) | 2002-07-31 | 2009-08-18 | Mercian Corporation | Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same |
| RU2338741C2 (ru) | 2002-07-31 | 2008-11-20 | Мершан Корпорейшн | Новые физиологически активные вещества |
| BR0316746A (pt) | 2002-11-29 | 2005-10-18 | Mercian Corp | Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550) |
| CA2546614A1 (en) | 2003-11-27 | 2005-06-09 | Mercian Corporation | Dna participating in hydroxylation of macrolide compound |
| WO2006009276A1 (ja) | 2004-07-20 | 2006-01-26 | Eisai R & D Management Co., Ltd. | プラジエノライドの生合成に関与するポリペプチドをコードするｄｎａ |
| CN101282967B (zh) | 2005-10-13 | 2011-01-26 | 卫材R&D管理有限公司 | 普拉二烯内酯b和普拉二烯内酯d的全合成 |
| JPWO2008111464A1 (ja) * | 2007-03-05 | 2010-06-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スプライシング異常を指標とする抗ガン剤の作用検定方法 |
| US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
| EP2331704B1 (en) | 2008-08-14 | 2016-11-30 | Nanostring Technologies, Inc | Stable nanoreporters |
| TW201204393A (en) * | 2010-04-16 | 2012-02-01 | Daiichi Sankyo Co Ltd | Diagnostic agent and therapeutic agent of cancer |
| AU2012336120B2 (en) * | 2011-11-08 | 2017-10-26 | Genomic Health, Inc. | Method of predicting breast cancer prognosis |
| WO2013086464A1 (en) * | 2011-12-07 | 2013-06-13 | The Broad Institute, Inc. | Markers associated with chronic lymphocytic leukemia prognosis and progression |
| JP6057408B2 (ja) | 2012-03-05 | 2017-01-11 | 国立大学法人 千葉大学 | 癌の予防剤および／または治療剤 |
| US20140275010A1 (en) * | 2013-03-12 | 2014-09-18 | Guo Zhu Zheng | Quaternary salts |
| WO2014165753A1 (en) | 2013-04-05 | 2014-10-09 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for diagnosis of glioblastoma or a subtype thereof |
| KR101710318B1 (ko) | 2014-05-15 | 2017-02-24 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 플라디에놀리드 피리딘 화합물 및 사용 방법 |
| EP3910073B1 (en) | 2015-09-01 | 2024-03-06 | Eisai R&D Management Co., Ltd. | Splice variants associated with neomorphic sf3b1 mutants |
-
2016
- 2016-08-30 EP EP21174658.1A patent/EP3910073B1/en active Active
- 2016-08-30 ES ES16766420T patent/ES2887201T3/es active Active
- 2016-08-30 JP JP2018510109A patent/JP6876680B2/ja active Active
- 2016-08-30 US US15/755,225 patent/US10889866B2/en active Active
- 2016-08-30 EP EP16766420.0A patent/EP3344780B1/en active Active
- 2016-08-30 WO PCT/US2016/049490 patent/WO2017040526A2/en not_active Ceased
-
2020
- 2020-11-16 US US17/098,940 patent/US11761045B2/en active Active
-
2021
- 2021-04-26 JP JP2021074145A patent/JP7256840B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525994A5 (OSRAM) | ||
| Cheng et al. | Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine | |
| Abbosh et al. | Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution | |
| Eyles et al. | Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma | |
| Biankin et al. | Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes | |
| Northcott et al. | Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma | |
| Riveiro-Falkenbach et al. | Intra-and inter-tumoral homogeneity of BRAFV600E mutations in melanoma tumors | |
| JP2017512491A5 (OSRAM) | ||
| JP2015210268A5 (OSRAM) | ||
| Bobba et al. | Scar carcinoma of the lung: a historical perspective | |
| JP2019510066A5 (OSRAM) | ||
| Tsai et al. | Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion | |
| JP2018513679A5 (OSRAM) | ||
| RU2018145532A (ru) | Композиции и способы диагностирования раковых заболеваний легких с помощью профилей экспрессии генов | |
| ES2947946T3 (es) | Métodos para predecir el riesgo de metástasis en melanoma cutáneo | |
| Matsuura et al. | CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma | |
| Masuda et al. | A case of dedifferentiated solitary fibrous tumor of the thoracic cavity | |
| Andea et al. | Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status | |
| US20190256920A1 (en) | Differential Identification of Pancreatic Cysts | |
| Dimitrakopoulos et al. | Variant of BCL3 gene is strongly associated with five-year survival of non-small-cell lung cancer patients | |
| KR20150132206A (ko) | 예측성 바이오마커에 대한 검정법 | |
| Jelovac et al. | The amplification of c-erb-B2 in cancer-free surgical margins is a predictor of poor outcome in oral squamous cell carcinoma | |
| EP4419668A1 (en) | Use of nanopore sequencing for determining the origin of circulating dna | |
| Shinmura et al. | A novel somatic FGFR3 mutation in primary lung cancer | |
| JP6860148B2 (ja) | 治療法の有利性を予見する予見方法 |